AB0218 NON MEDICAL SWITCH FROM ADALIMUMAB ORIGINATOR TO THE BIOSIMILAR GP2017 IN PATIENTS AFFECTED BY CHRONIC ARTHRITIS

Background: The non-medical switch (NMS) from originator drugs to biosimilars is a possible strategy adopted by rheumatologists in order control the expansion of pharmaceutic costs for treatment fo patients affected chronic arthritis. To date, few real life data on adalimumab (ADA) its are available. Objectives: We aimed evaluate efficacy and safety single-Centre cohort arthritis who switched ADA biosimilar GP2017. Methods: Patients rheumatoid (RA), psoriatic (PA) axial spondyloarthritis (axSpA) already therapy with remission or low disease activity at least 6 months were GP2017 (March- June 2020). Data (DAS28-PCR/CDAI/SDAI; DAPSA; BASDAI), eventual adverse events causes withdrawal collected 2, 4 after switch. Results: 88 enrolled (M/F 36/52; mean age 55.8 ± 12 years; 25 RA, 32 PA, 31 axSpA, duration 6.3 3.8 years). No statistically significant difference was observed median DAS28-PCR/CDAI/SDAI values baseline [1.03 (0.96-3.43) vs. 1.21 (0-3.7) / 0 (0-15) (0-17) 0.5 (0-17.5)], DAPSA [0 (0-12.2) (0-15)] BASDAI (0-4.3) (0-6.4)]. retention rate 93.2%. 6/88 (6.8%) back originator. discontinuation were: reactivation single case (1.1%), subjective reasons/nocebo effect 5/88 cases (5.7%), including: general malaise transient increased blood pressure (n.1), dizziness, paraesthesia, arthralgia, headache itch sine materia (n.1) worsening without objective flare (n.2). Conclusion: This first study showing that NMS represents safe practice maintains current treatment. However, switchback described, mainly attributed nocebo [1]. References: [1]Fleischmann R, Jairath V, Mysler E et al . Nonmedical Switching From Originators Biosimilars: Does Nocebo Effect Explain Treatment Failures Adverse Events Rheumatology Gastroenterology? Rheumatol Ther 7: 35–64 (2020). Disclosure Interests: None declared